TG Therapeutics Inc (TGTX) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
Total Cash From Operating Activities Chart for TG Therapeutics Inc
TG Therapeutics Inc (TGTX) operating cash flow for FY2025 was USD -24.8M. TG Therapeutics Inc's operating cash flow moved from USD -4.0M in 1996 to USD -24.8M in 2025 over 29 years.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $9.37B
- Implied Share Price
- $61.18
- Enterprise Value
- $9.57B
- Revenue (TTM)
- $799.54M
- EBITDA
- $136.45M
- Profit Margin
- 55.22%
- Trailing P/E
- 22.25
- Forward P/E
- 28.33
- Price/Book (MRQ)
- 15.50
- Price/Sales (TTM)
- 11.71
- EV/EBITDA
- 68.63
- EV/Revenue
- 11.97
- Dividend Yield
- —
- Book Value
- $4.26
- Free Cash Flow (FY2025)
- -$24.99M
- Free Cash Flow Yield
- -0.27%
Snapshot as of 1st November 2026 — not point-in-time controlled, may lag the live market by a few days.